Department: Department: Global Patient Safety, Novo Nordisk Global Business Services (GBS)
As Safety Surveillance Specialist, you will help establish and protect the safety profile of Novo Nordisk products across Diabetes, Obesity and Rare Diseases. You will turn data from clinical trials, spontaneous reports, literature and post-marketing sources into clear signals, safety strategies and benefit-risk conclusions. Your medical judgement will help identify concerns early and keep safe-ty information accurate throughout each product’s lifecy-cle – so people living with serious chronic diseases, and those who treat them, can rely on it.
You are a physician with deep pharmacovigilance experience who is ready to shape safety strategy, not only apply it. You will bring:
You will join the Safety Surveillance Adviser team in Global Patient Safety in Bangalore, part of Novo Nordisk Global Business Services. The team monitors, evaluates and communicates the safety profile of Novo Nordisk products across their lifecycle, contributing to safety surveillance across the Diabetes, Obesity and Rare Diseases portfolios.
You will work closely with global hubs in Copenhagen and other partner teams, as well as colleagues across functions in a matrix environment. Externally, you will engage with regulatory authorities, consultants and partners on safety-related topics. Building strong relationships across these groups helps the team act on signals quickly and speak with one clear voice on safety.
You will also coach and mentor team members, sharing your expertise to raise the capability of the team around you.
You will work on medicines used by many people around the world, where your medical expertise directly shapes how safety is assessed, managed and communicated. You will be trusted to own your conclusions, make your voice heard in governance and regulatory discussions and help decide how the team works – from strategy to process improvements.
We care for people and never compromise on patient safety. At the same time, we calibrate our standards to the situation and act with clarity and urgency, so safety in-sights lead to timely decisions. You will grow alongside experienced colleagues in Bangalore and Copenhagen, and help others grow through coaching and mentoring.
Your impact begins today. If you are ready to lead safety surveillance that people living with serious chronic diseases can rely on, apply for the Safety Surveillance Specialist – Global Patient Safety role by 26 October 2026.
We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html